Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHLW Extends Roche's Tamiflu Valid-Use Period To Seven Years

This article was originally published in PharmAsia News

Executive Summary

The ministry of Health, Labor and Welfare Nov. 12 approved an extension of the valid-use period for Tamiflu from five years to seven years. The extension will be also applied to existing stockpiles. According to Chugai Pharmaceutical, the drug's importer and marketing company in Japan, there are no safety and effectiveness issues. Last year, U.S. FDA approved a two year extension of Tamiflu's expiration date. Since 2005, the Japanese government has spent ¥54.4 billion and stockpiled Tamiflu for 24 million people, and next year, the government plans to stockpile the drug for an additional 26 million. The extension will save several billion yen per year. (Click here for more - Japanese language

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel